| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
4578 Stock Overview
Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide.
Otsuka Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥4,146.00 |
| 52 Week High | JP¥5,013.00 |
| 52 Week Low | JP¥4,017.00 |
| Beta | 0.51 |
| 1 Month Change | -7.74% |
| 3 Month Change | -12.81% |
| 1 Year Change | -3.42% |
| 3 Year Change | -23.11% |
| 5 Year Change | -7.66% |
| Change since IPO | 93.74% |
Recent News & Updates
Shareholder Returns
| 4578 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -0.3% | -4.2% | -4.6% |
| 1Y | -3.4% | -10.2% | 8.9% |
Return vs Industry: 4578 exceeded the JP Pharmaceuticals industry which returned -10.2% over the past year.
Return vs Market: 4578 underperformed the JP Market which returned 8.9% over the past year.
Price Volatility
| 4578 volatility | |
|---|---|
| 4578 Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in JP Market | 8.0% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4578 is less volatile than 75% of JP stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 4578's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1921 | 33,151 | Tatsuo Higuchi | https://www.otsuka.com |
Otsuka Holdings Co., Ltd. engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of oncology, cardiovascular system, renal system, digestive system, ophthalmology, diagnostics, and intravenous solutions, as well as medical devices businesses. It also provides EQUELLE, a product for women's health and beauty; BODYMAINTÉ Jelly, a conditioning food product; BODYMAINTÉ Drink, a drinkable-liquid; POCARI SWEAT, a drink; Calorie Mate, a nutritional food; OS-1, an oral rehydration solution; HINEX-R, a concentrated liquid diet; and Oronine H Ointment, a household antiseptic medicine.
Otsuka Holdings Fundamentals Summary
| 4578 fundamental statistics | |
|---|---|
| Market Cap | JP¥2.19t |
| Earnings (TTM) | JP¥147.02b |
| Revenue (TTM) | JP¥1.46t |
0.0x
P/E Ratio0.0x
P/S RatioIs 4578 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4578 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.46t |
| Cost of Revenue | JP¥469.91b |
| Gross Profit | JP¥993.38b |
| Expenses | JP¥846.36b |
| Earnings | JP¥147.02b |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 67.89% |
| Net Profit Margin | 10.05% |
| Debt/Equity Ratio | 7.0% |
How did 4578 perform over the long term?
See historical performance and comparisonDividends
2.4%
Current Dividend Yield18%
Payout RatioDoes 4578 pay a reliable dividends?
See 4578 dividend history and benchmarks| Otsuka Holdings dividend dates | |
|---|---|
| Ex Dividend Date | Dec 29 2021 |
| Dividend Pay Date | Mar 31 2022 |
| Days until Ex dividend | 28 days |
| Days until Dividend pay date | 120 days |
Does 4578 pay a reliable dividends?
See 4578 dividend history and benchmarksValuation
Is Otsuka Holdings undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 4578 (¥4146) is trading below our estimate of fair value (¥8641.41)
Significantly Below Fair Value: 4578 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: Insufficient data to calculate 4578's PE Ratio to determine if it is good value compared to the JP Pharmaceuticals industry average.
PE vs Market: Insufficient data to calculate 4578's PE Ratio to determine if it is good value compared to the JP market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4578's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: Insufficient data to calculate 4578's PB Ratio to determine if it is good value.
Future Growth
How is Otsuka Holdings forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
2.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4578's forecast earnings growth (2% per year) is above the savings rate (0.02%).
Earnings vs Market: 4578's earnings (2% per year) are forecast to grow slower than the JP market (10.3% per year).
High Growth Earnings: 4578's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4578's revenue (1.9% per year) is forecast to grow slower than the JP market (4.9% per year).
High Growth Revenue: 4578's revenue (1.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4578's Return on Equity is forecast to be low in 3 years time (8.1%).
Past Performance
How has Otsuka Holdings performed over the past 5 years?
13.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4578 has high quality earnings.
Growing Profit Margin: 4578's current net profit margins (10%) are higher than last year (10%).
Past Earnings Growth Analysis
Earnings Trend: 4578's earnings have grown by 13% per year over the past 5 years.
Accelerating Growth: 4578's earnings growth over the past year (2.5%) is below its 5-year average (13% per year).
Earnings vs Industry: 4578 earnings growth over the past year (2.5%) underperformed the Pharmaceuticals industry 9.3%.
Return on Equity
High ROE: 4578's Return on Equity (7.5%) is considered low.
Financial Health
How is Otsuka Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 4578's short term assets (¥1,064.1B) exceed its short term liabilities (¥484.6B).
Long Term Liabilities: 4578's short term assets (¥1,064.1B) exceed its long term liabilities (¥313.5B).
Debt to Equity History and Analysis
Debt Level: 4578 has more cash than its total debt.
Reducing Debt: 4578's debt to equity ratio has reduced from 16.9% to 7% over the past 5 years.
Debt Coverage: 4578's debt is well covered by operating cash flow (140%).
Interest Coverage: 4578 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Otsuka Holdings's current dividend yield, its reliability and sustainability?
2.41%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 4578's dividend (2.41%) is higher than the bottom 25% of dividend payers in the JP market (1.41%).
High Dividend: 4578's dividend (2.41%) is low compared to the top 25% of dividend payers in the JP market (3.33%).
Stability and Growth of Payments
Stable Dividend: 4578's dividend payments have been volatile in the past 10 years.
Growing Dividend: 4578's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (18.4%), 4578's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.7yrs
Average management tenure
CEO
Tatsuo Higuchi (71 yo)
no data
Tenure
JP¥244,000,000
Compensation
Mr. Tatsuo Higuchi has been the President and Executive Director of Otsuka Holdings Co., Ltd. since July 2008 and serves as its Chief Executive Officer. Mr. Higuchi has been the President of Otsuka Pharmac...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Tatsuo's total compensation is reasonable compared to companies of similar size in the JP market.
Compensation vs Earnings: Tatsuo's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: 4578's management team is considered experienced (3.7 years average tenure).
Board Members
Experienced Board: 4578's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.
Top Shareholders
Company Information
Otsuka Holdings Co., Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: Otsuka Holdings Co., Ltd.
- Ticker: 4578
- Exchange: TSE
- Founded: 1921
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥2.186t
- Shares outstanding: 542.40m
- Website: https://www.otsuka.com
Number of Employees
Location
- Otsuka Holdings Co., Ltd.
- 2-9 Kanda-Tsukasamachi
- Chiyoda-ku
- Tokyo
- 101-0048
- Japan
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/11/30 09:19 |
| End of Day Share Price | 2021/11/30 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.